An update on some recent trials of drugs using cancer stem cell-based (CSC) knowledge and technology, where the results are promising but not conclusive. Conclusion:
Like most things in biology, I suspect the truth lies somewhere in between the extremes. The evidence supporting the CSC hypothesis seems compelling, although several factors — long-term quiescence, multiple protein expression characteristics, and clonal evolution — suggest that definitive clinical proof will be a challenge. Moreover, it’s possible that some cancers will follow the CSC model, whereas others may not.